BridgeBio rises as late-stage trial of muscle-wasting drug meets all goals
27/10/2025 13:48
Updates ** Shares of drugmaker BridgeBio Pharma BBIO.O rise 10.5% to $60, highest in over four years ** Co says its experimental drug BBP-418 met all the goals in a late-stage trial for a type of limb-girdle muscular dystrophy, a rare muscle-wasting disease ** Drug boosted levels of key muscle protein and cut muscle damage marker CK by 82% from initial levels- BBIO ** Co says treated patients showed better walking speed and lung function vs placebo at 12 months ** BBIO plans to file for U.S. FDA approval in first half of 2026 ** Including session's move, stock up ~98% YTD (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels